Integrating Frontline Biomarkers and Multidisciplinary Teams in Prostate Cancer

Modern metastatic prostate cancer management is undergoing a significant shift toward precision medicine, requiring comprehensive biomarker testing and collaborative care, according to Manojkumar Bupathi, MD, MS. Rather than relying on a one-size-fits-all strategy, selection of therapy must be tailored based on a detailed assessment of both tumor genetics and clinical factors. Because of new therapies that have been approved in metastatic hormone-sensitive prostate cancer, clinicians need to perform upfront testing for specific genomic alterations, including BRCA mutations, PTEN loss, RB1, and TP53, using germline and somatic testing.

Tumor genetics are then integrated with clinical characteristics, such as disease volume, Gleason score, sites of visceral or bone involvement, and baseline patient factors, including comorbidities and blood counts.

These comprehensive evaluations directly guide therapeutic selection. Patients harboring a PTEN loss are now appropriate candidates for targeted capivasertib (Truqap) combinations, whereas those with BRCA mutations can derive greater benefit from PARP inhibitors. For individuals presenting with extensive, high-volume disease lacking actionable genomic alterations, they can now consider radioligand therapy, such as lutetium Lu-177 vipivotide tetraxetan (Pluvicto) before systemic chemotherapy. In cases without identified biomarker drivers, standard treatment remains a triplet or doublet regimen consisting of androgen deprivation therapy, an androgen receptor pathway inhibitor, and chemotherapy.

This paradigm shift requires a notable operational adjustment for community and academic oncologists. Genomic profiling, historically reserved for late-stage, castration-resistant disease, must now be integrated upfront at initial diagnosis to guide early treatment decisions. Navigating this and other choices now being made earlier on requires strong multidisciplinary collaboration among urology, medical oncology, and radiation oncology teams, Bupathi argues. To overcome implementation challenges, he encourages leverage educational resources, consulting clinical trial research networks and experts, or establishing recurring multidisciplinary tumor boards or working groups to systematically review patient cases.